Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, forecasts that sales of Genentech/Roche/Chugai's Herceptin will nearly triple to more than $2 billion by 2009. According to a new Pharmacor study entitled Breast Cancer, a major driver of Herceptin's sales is its increased use by European physicians in metastatic patients and its launch in all markets for adjuvant use.

"We anticipate that the ongoing pivotal trials of adjuvant trastuzumab (Herceptin) will show positive results. As a result, trastuzumab will be incorporated into the adjuvant treatment of high-risk patients who overexpress HER2," said Joanne Graham, Ph.D., analyst at Decision Resources. "The value of the adjuvant market is higher than that of the metastatic market because the patient pool is bigger and treatment duration is increased, so sales of trastuzumab will continue to climb through 2014."

About Breast Cancer

Breast cancer is the most common cancer in women, accounting for 23% of all cancer, and the second most common cause of malignancy-related death worldwide. Although the incidence of breast cancer is rising in the seven major pharmaceutical markets we cover, more women are surviving the disease thanks to advances in screening and treatment, and even those who are not cured are living longer.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources, Inc., ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,

Antidepressants Will Drive Growth in the Chronic Low Back Pain Market

View Now